Core Viewpoint - The company Kyushu Tong (600998) reported a total sales revenue of 14.728 billion yuan from its agency brand promotion business (including pharmaceuticals and medical devices) in the first three quarters of 2025, indicating a strong performance in this sector [1] Company Performance - The pharmaceutical agency brand promotion business generated a sales revenue of 8.740 billion yuan in the first three quarters of 2025, reflecting a year-on-year growth of 15.26% [1] - Key products contributing to this growth include well-known brands such as Kewai (Oseltamivir Phosphate), Kangwang, Mikobao, Betaloc, and Pairisong [1]

Core Viewpoint - 九州通's total brand promotion business (CSO) achieved a sales revenue of 14.728 billion yuan in the first three quarters of 2025, demonstrating steady growth [1] Group 1: Pharmaceutical CSO Business - The pharmaceutical CSO business generated a sales revenue of 8.740 billion yuan, reflecting a year-on-year growth of 15.26%, primarily driven by the strong performance of core products such as 可威 and 弥可保 [1] - The company has introduced 81 new product specifications during the period, including 9 high-value products, and has secured the distribution rights for 8 specifications of 卡泊三醇 in retail channels through collaboration with 利奥中国 [1] - 九州通's platforms, including 全擎健康, currently represent 783 product specifications, with 32 products achieving annual sales exceeding 100 million yuan, covering chronic diseases and anti-infection areas [1] Group 2: Medical Device CSO Business - The medical device CSO business recorded a sales revenue of 5.987 billion yuan, facing challenges due to the impact of medical consumables procurement policies on certain products like ultrasound knives and staplers [1] - The company represents 1,386 product specifications from 11 major manufacturers, including brands like 强生, 罗氏, and 雅培, across 15 product lines [1] - New product introductions, such as 登士柏 (dental) and 加奇, have shown rapid growth, with sales revenue exceeding 180 million yuan in the first three quarters [1]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 6.30 CNY, based on a 14x PE ratio for 2025 [3][5]. Core Insights - The company has shown a steady growth in its pharmaceutical distribution business, achieving a revenue of 119.3 billion CNY in the first three quarters of 2025, representing a year-on-year increase of 5.2%. The net profit attributable to the parent company reached 1.98 billion CNY, up 16.5% year-on-year [9]. - New business segments, particularly digital logistics, are expected to continue their rapid growth, with revenue from digital logistics and supply chain solutions increasing by 25.0% year-on-year [9]. - The company is actively introducing new products, with 81 new agency drugs added in the first three quarters of 2025, contributing to a strong profit growth momentum in the CSO business [9]. Financial Performance Summary - Revenue projections for the company are as follows: - 2023: 150.14 billion CNY - 2024: 151.81 billion CNY - 2025: 162.73 billion CNY (7.2% growth) - 2026: 174.35 billion CNY (7.1% growth) - 2027: 186.71 billion CNY (7.1% growth) [4][10] - The net profit attributable to the parent company is projected to be: - 2023: 2.17 billion CNY - 2024: 2.51 billion CNY - 2025: 2.27 billion CNY (9.4% decline) - 2026: 2.38 billion CNY (4.6% growth) - 2027: 2.69 billion CNY (13.1% growth) [4][10]. - The earnings per share (EPS) forecast is: - 2023: 0.43 CNY - 2024: 0.50 CNY - 2025: 0.45 CNY - 2026: 0.47 CNY - 2027: 0.53 CNY [4][10].

Core Viewpoint - The company has demonstrated strong financial performance in the third quarter of 2025, with significant growth in revenue and net profit, driven by its strategic focus on new products, new retail, and digital logistics. Financial Performance - In Q3 2025, the company achieved a year-on-year increase in operating revenue, net profit attributable to shareholders, and net profit excluding non-recurring gains and losses of 5.41%, 8.46%, and 15.24% respectively [4] - Compared to Q2 2025, net profit attributable to shareholders increased by 11.39%, and net profit excluding non-recurring gains and losses rose by 16.49% [4] - For the first three quarters of 2025, operating revenue and net profit attributable to shareholders grew by 5.20% and 16.46% respectively, supported by steady growth in pharmaceutical distribution and emerging business segments [4] Business Segments New Products Strategy - The company’s brand promotion business achieved sales revenue of 147.28 billion yuan in the first three quarters of 2025, with a focus on expanding product varieties [7] - The pharmaceutical brand promotion business saw a 15.26% year-on-year increase in sales revenue, driven by strong sales of core products [8] - The company introduced 81 new products during the period, including several high-value items [8] New Retail Strategy - The company’s "Good Pharmacist" franchise reached 33,275 stores nationwide, with a 43.40% year-on-year increase in sales revenue from franchise stores [15] - The B2C e-commerce segment generated 8.17 billion yuan in sales revenue, marking a 13.00% increase [17] Digital Logistics and Supply Chain Solutions - The digital logistics and supply chain solutions business achieved revenue of 9.18 billion yuan, reflecting a 24.95% growth [37] - The company has established a comprehensive intelligent pharmaceutical logistics network covering 96% of the country [38] Digital Transformation - The company invested 2.29 billion yuan in R&D in the first three quarters of 2025, with a focus on AI applications across various business scenarios [25] - The company has developed a digital platform that integrates logistics, software, and operational services, enhancing efficiency and customer satisfaction [39] Real Estate Investment Trusts (REITs) - The company’s REITs have performed well since their listing, with a cumulative increase of 43.28% in share price by September 30, 2025 [28] - The company has a robust portfolio of logistics assets, supporting its REITs strategy and ensuring stable business growth [29] Talent Strategy - The company has successfully recruited 572 key personnel in various strategic areas, with a 74.30% increase in talent acquisition costs compared to the previous year [40]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 6.30 CNY based on a 14x PE ratio for 2025 [3][6]. Core Views - The company has shown steady revenue growth, with a 5.1% year-on-year increase in H1 2025, achieving a revenue of 811.1 billion CNY and a net profit of 14.5 billion CNY, which is a 19.7% increase year-on-year [10]. - The company is actively pursuing strategic transformation, focusing on enhancing its operational efficiency and expanding its market presence in new retail and e-commerce channels [10]. - The financial forecasts for 2025-2027 have been adjusted, with expected earnings per share of 0.45, 0.47, and 0.53 CNY respectively, reflecting a downward revision from previous estimates [3][5]. Financial Summary - The company's revenue is projected to grow from 150.14 billion CNY in 2023 to 186.71 billion CNY in 2027, with a compound annual growth rate (CAGR) of approximately 7.1% [5][12]. - Operating profit is expected to decline in 2025 to 3.36 billion CNY, down from 3.64 billion CNY in 2024, before recovering to 3.97 billion CNY in 2027 [5][12]. - The net profit attributable to the parent company is forecasted to decrease to 2.27 billion CNY in 2025, with a subsequent increase to 2.68 billion CNY by 2027 [5][12]. - The gross margin is expected to stabilize around 7.8% from 2025 to 2027, while the net margin remains consistent at 1.4% [5][12].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 6.30 CNY based on a 14x PE ratio for 2025 [3][6]. Core Views - The company has shown steady revenue growth, with a projected increase in revenue from 150.14 billion CNY in 2023 to 186.71 billion CNY by 2027, reflecting a CAGR of approximately 7.1% [5][10]. - The net profit attributable to the parent company is expected to decline slightly in 2025 to 2.27 billion CNY, before recovering to 2.68 billion CNY in 2027, indicating a focus on strategic transformation and operational efficiency [5][10]. - The company is actively pursuing a strategic transformation, focusing on new retail operations and enhancing its product offerings, including a significant increase in medical beauty revenue by 48.6% in the first half of 2025 [10]. Financial Summary - Revenue projections for 2025-2027 are adjusted to 162.73 billion CNY, 174.35 billion CNY, and 186.71 billion CNY respectively, with corresponding net profits of 2.27 billion CNY, 2.38 billion CNY, and 2.69 billion CNY [5][10]. - The gross margin is expected to stabilize around 7.8% from 2025 onwards, while the net margin remains consistent at 1.4% [5][10]. - The company’s operating profit is forecasted to decrease by 7.5% in 2025, followed by a recovery in subsequent years, indicating a focus on cost management and efficiency improvements [5][10].

Core Viewpoint - The report highlights the financial performance and strategic initiatives of Jiuzhoutong Pharmaceutical Group Co., Ltd. for the first half of 2025, showcasing growth in revenue and net profit despite challenges in receivables and increased impairment provisions. Financial Performance - Total assets at the end of the reporting period amounted to approximately 107.77 billion RMB, a decrease of 5.25% compared to the end of the previous year [1] - Operating revenue reached approximately 81.11 billion RMB, with a net profit attributable to shareholders of approximately 9.52 billion RMB, reflecting a year-on-year increase of 19.70% [2][3] - The net profit after deducting non-recurring gains and losses was approximately 951.86 million RMB, down 19.34% year-on-year, primarily due to increased impairment provisions related to receivables [2][3] - Cash flow from operating activities showed a net outflow of approximately 2.82 billion RMB, an improvement of 11.87% compared to the previous year [1] Business Segments and Growth - The core pharmaceutical distribution business generated sales revenue of approximately 67.63 billion RMB, a year-on-year increase of 6.04% [8] - Emerging business segments such as pharmaceutical manufacturing and digital logistics reported significant growth, with pharmaceutical manufacturing achieving a revenue increase of 10.77% to approximately 1.59 billion RMB, and digital logistics growing by 24.66% to approximately 587 million RMB [8] - The new retail business, including the "Good Medicine" franchise, expanded to 31,535 stores, with sales revenue reaching approximately 3.42 billion RMB, a growth of 41.30% [18] Strategic Initiatives - The company is focusing on digital transformation, with a research and development investment of approximately 146 million RMB aimed at enhancing AI applications across various business functions [9] - The implementation of the "Three New and Two Transformations" strategy has led to the establishment of a comprehensive service model integrating pharmaceutical distribution, logistics, and product promotion [4][10] - The company has actively engaged in ESG initiatives, contributing approximately 11.38 million RMB to various social causes and achieving high ratings in ESG assessments [6][7] Market Position and Recognition - Jiuzhoutong is recognized as the largest private pharmaceutical commercial enterprise in China and ranked 165th in the "China Enterprise 500" list [5] - The company has received multiple awards for its investor relations management and was recognized as a model enterprise in ESG practices [5][7] - The company's credit rating was upgraded to AAA, reflecting strong market confidence and potentially lowering financing costs [7]

Performance - In 2024, the company achieved total operating revenue of 151.81 billion, a year-on-year increase of 1.11%; net profit attributable to shareholders was 2.51 billion, up 15.33%; and net profit excluding non-recurring items was 1.81 billion, down 7.47% [1] - In Q1 2025, total operating revenue reached 42.02 billion, a year-on-year increase of 3.82%; net profit attributable to shareholders was 970 million, a significant increase of 80.38%; and net profit excluding non-recurring items was 507 million, down 2.76% [1] Growth Potential - The company successfully launched its REITs, marking a new chapter in light asset operations, with the public offering of pharmaceutical warehousing logistics REITs raising 1.16 billion on February 27, 2025 [2] - The CSO business continued to grow, achieving sales revenue of 19.27 billion, with pharmaceutical CSO revenue at 10.77 billion, a year-on-year increase of 19.59% after adjusting for high base effects [2] New Retail and New Medical - The "Good Pharmacist" franchise rapidly expanded, reaching 29,331 stores by the end of March 2025, with sales to franchise pharmacies amounting to 5.39 billion, a year-on-year increase of 54.94% [3] - The "Nine Medical Clinics" membership stores reached 1,377 by the end of March 2025, utilizing AI-assisted diagnostic platforms to empower grassroots medical institutions [3] Profitability - The overall gross margin for 2024 was 7.80%, a decrease of 0.27 percentage points, while Q1 gross margin was 7.33%, an increase of 0.13 percentage points [4] - The net profit margin attributable to shareholders for 2024 was 1.65%, an increase of approximately 0.21 percentage points, with Q1 2025 net profit margin at 2.31%, a significant increase of 0.98 percentage points [4] Operating Quality - The net cash flow from operating activities in 2024 was 3.08 billion, a year-on-year decrease of 35.07%, primarily due to increased procurement payments from strategic cooperation with core suppliers [5] - By Q1 2025, the company's operating cash flow remained stable year-on-year, with slight increases in accounts receivable turnover days and inventory turnover days [5] Profit Forecast and Valuation - Revenue projections for 2025-2027 are 163.29 billion, 176.46 billion, and 190.08 billion, with corresponding growth rates of 7.56%, 8.06%, and 7.72% [6] - Expected net profits attributable to shareholders for the same period are 2.84 billion, 3.18 billion, and 3.54 billion, with year-on-year growth rates of 13.13%, 12.08%, and 11.21% [6]